Genetically distinct ASD subtypes: is mtor dysregulation a common mechanism?

The Defense Health Agency awarded a $863,500 Project Grant to Rutgers, The State University of New Jersey under the Military Medical Research and Development federal grant program (CFDA 12.420). The three-year award beginning September 1, 2022 will support research into "Genetically Distinct ASD Subtypes: Is MTOR Dysregulation a Common Mechanism?"

Through this funding, Rutgers researchers will investigate potential connections between mutations in the MTOR gene pathway and autism spectrum disorder (ASD) subtypes. The project aims to advance understanding of distinct ASD subtypes at the genetic and biological level. Insights gained could inform more targeted and personalized treatment approaches for individuals with ASD. By exploring common disease mechanisms, the research also seeks to transform military and public health care through innovative medical solutions applicable on the battlefield and beyond.